Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme

Myrthe J van Dijk, Jonathan R A de Wilde, Marije Bartels, Kevin H M Kuo, Andreas Glenthøj, Minke A E Rab, Eduard J van Beers, Richard van Wijk*

*Corresponding author af dette arbejde

Abstract

Novel developments in therapies for various hereditary hemolytic anemias reflect the pivotal role of pyruvate kinase (PK), a key enzyme of glycolysis, in red blood cell (RBC) health. Without PK catalyzing one of the final steps of the Embden-Meyerhof pathway, there is no net yield of adenosine triphosphate (ATP) during glycolysis, the sole source of energy production required for proper RBC function and survival. In hereditary hemolytic anemias, RBC health is compromised and therefore lifespan is shortened. Although our knowledge on glycolysis in general and PK function in particular is solid, recent advances in genetic, molecular, biochemical, and metabolic aspects of hereditary anemias have improved our understanding of these diseases. These advances provide a rationale for targeting PK as therapeutic option in hereditary hemolytic anemias other than PK deficiency. This review summarizes the knowledge, rationale, (pre)clinical trials, and future advances of PK activators for this important group of rare diseases.

OriginalsprogEngelsk
Artikelnummer101103
TidsskriftBlood reviews
Vol/bind61
ISSN0268-960X
DOI
StatusUdgivet - sep. 2023

Fingeraftryk

Dyk ned i forskningsemnerne om 'Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme'. Sammen danner de et unikt fingeraftryk.

Citationsformater